SAR-439459

DB17864InvestigationalProtein Based Therapies

SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody. Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

Mechanism: Pharmacologically active on Transforming growth factor beta-1 proprotein, Transforming growth factor beta-2 proprotein, and Transforming growth factor beta-3 proprotein
Curator reviewed
Also known as: ANTI-TGF-BETA MONOCLONAL ANTIBODY SAR-439459 · MAB HUMAN (IGG4) ANTI P01137 (TGFB1_HUMAN) OR ANTI P61812 (TFGB2_HUMAN) OR ANTI P10600 (TGFB3_HUMAN)(SAR439459)
Code names: GC-2008 · SAR-439459

Resolves to

Compound

UNII7EFI23P78R

Targets

P01137TGFB1P61812TGFB2P10600TGFB3

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with SAR-439459, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account